{
    "clinical_study": {
        "@rank": "72432", 
        "arm_group": {
            "arm_group_label": "Arm I", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive oral R115777 twice daily for 21 consecutive days. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "Phase II trial to study the effectiveness of R115777 in treating patients who have\n      metastatic pancreatic cancer. Drugs used in chemotherapy use different ways to stop tumor\n      cells from dividing so they stop growing or die."
        }, 
        "brief_title": "R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer", 
        "condition": "Pancreatic Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Pancreatic Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the safety and effectiveness of R115777 in patients with metastatic pancreatic\n      cancer.\n\n      II. Determine the response rate, time to progression, and 6 month survival rate of these\n      patients with this treatment regimen.\n\n      III. Assess the pharmacokinetics of this treatment regimen in this patient population.\n\n      OUTLINE: This is a multicenter study.\n\n      Patients receive oral R115777 twice daily for 21 consecutive days. Treatment continues every\n      28 days in the absence of disease progression or unacceptable toxicity.\n\n      Patients are followed every 3 months for 1 year."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically confirmed adenocarcinoma of the pancreas\n\n          -  Measurable metastatic disease No prior treatment for metastatic disease except\n             immunotherapy (e.g., antibodies, vaccines, cytokines)\n\n        PATIENT CHARACTERISTICS:\n\n          -  Age: 18 and over\n\n          -  Performance status: ECOG 0-2\n\n          -  WBC at least 4,000/mm3 OR granulocyte count at least 1,500/mm3\n\n          -  Platelet count at least 100,000/mm3\n\n          -  Bilirubin no greater than 2.0 mg/dL\n\n          -  SGOT/SGPT no greater than 2 times normal\n\n          -  Creatinine no greater than 2.0 mg/dL OR creatinine clearance at least 50 mL/min\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception during and for 3 months after the\n             study\n\n          -  No concurrent illness or active infection which would preclude study\n\n          -  No prior malignancy allowed unless disease free for the time period considered\n             appropriate for cure of the specific cancer\n\n          -  No history of allergies to imidazole compounds (e.g., fluconazole, ketoconazole,\n             miconazole, itraconazole, clotrimazole)\n\n        PRIOR CONCURRENT THERAPY:\n\n          -  No prophylactic filgrastim (G-CSF), sargramostim (GM-CSF), or thrombopoietin\n\n          -  Primary neoadjuvant or adjuvant chemotherapy allowed at least 6 months prior to\n             detection of metastatic disease\n\n          -  Primary radiotherapy allowed at least 6 months prior to detection of metastatic\n             disease\n\n          -  No concurrent use of proton pump inhibitors (e.g., omeprazole)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 2, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005843", 
            "org_study_id": "NCI-2012-02335", 
            "secondary_id": [
                "FCCC-00005", 
                "NCI-45", 
                "CDR0000067859"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Arm I", 
            "intervention_name": "tipifarnib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Tipifarnib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "recurrent pancreatic cancer", 
            "adenocarcinoma of the pancreas", 
            "stage IV pancreatic cancer"
        ], 
        "lastchanged_date": "February 8, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/FCCC-00005"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19111"
                    }, 
                    "name": "Fox Chase Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030-4009"
                    }, 
                    "name": "University of Texas - MD Anderson Cancer Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial of R115777 (NSC-702818), an Inhibitor of Farnesyl Protein Transferase, in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma", 
        "overall_official": {
            "affiliation": "Fox Chase Cancer Center", 
            "last_name": "Neal J. Meropol, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2004", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005843"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "12663718", 
            "citation": "Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol. 2003 Apr 1;21(7):1301-6."
        }, 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "May 2000", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2007"
    }, 
    "geocoordinates": {
        "Fox Chase Cancer Center": "39.952 -75.164", 
        "University of Texas - MD Anderson Cancer Center": "29.76 -95.369"
    }
}